IP Library › Granted Patent US 12,202,900
Granted Patent B2
US 12,202,900 · App. 16/435,166 · Granted Jan 21, 2025

Compositions and methods for treating immune thrombocytopenia

Inventors: Hans De Haard (Oudelande, NL); Peter Ulrichts (Destelbergen, BE); Thierry Cousin (Bordeaux, FR); Nicolas Leupin (Zurich, CH); Torsten Dreier (Sint Martens Latem, BE); Tonke Van Bragt (Boxtel, NL)
Assignee: argenx BV
C07K16/283C07K14/4703A61K45/06C07K2317/41C07K2317/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,202,900
App. No.
16/435,166
Granted
Jan 21, 2025
Kind
B2
Abstract

A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists.

Claims (14)

1. A method of treating a human subject that has newly diagnosed, persistent, or chronic immune thrombocytopenia (ITP), the method comprising administering to the subject a human neonatal Fc receptor (hFcRn) antagonist, wherein the hFcRn antagonist is administered intravenously once weekly at a dose of about 5 mg/kg to about 10 mg/kg at least four times, wherein the hFcRn antagonist consists of a variant Fc region consisting of two Fc domains which form a homodimer, wherein the amino acid sequence of each of the Fc domains consists of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, wherein the human subject has a platelet count of ≤30×10 9 /L on standard-of-care treatment with at least one compound approved for standard-of-care treatment for ITP prior to administering the hFcRn antagonist, and wherein the subject achieves a platelet count of >50×10 9 /L after administering four doses of the hFcRn antagonist, thereby treating the subject.

2. The method of claim 1 , wherein the hFcRn antagonist is efgartigimod.

3. The method of claim 2 , wherein the efgartigimod is administered intravenously at a dose dosage of about 5 mg/kg or about 10 mg/kg.

4. The method of claim 1 , wherein the human subject has a platelet count of less than 30×10 9 /L prior to administering the hFcRn antagonist.

5. The method of claim 1 , wherein the human subject receives one or more doses of at least one compound approved for standard-of-care treatment for ITP.

6. The method of claim 1 , wherein the human subject has persistent or chronic ITP.

7. The method of claim 5 , wherein the compound approved for standard-of-care treatment for ITP is selected from the group consisting of corticosteroids, romiplostim, eltrombopag, avatrombopag, cyclosporine, dapsone, danazol, azathioprine, intravenous immunoglobulin (IVIg), Rho(D) immune globulin (anti-D), rituximab, fostamatinib, and alemtuzumab.

8. The method of claim 1 , wherein the human subject has chronic ITP.

9. The method of claim 2 , wherein the efgartigimod is administered intravenously at a dose of about 10 mg/kg.

10. The method of claim 9 , wherein the efgartigimod is administered intravenously at a dose of about 10 mg/kg every two weeks after administering the first four doses.

11. The method of claim 5 , wherein the at least one compound approved for standard-of-care treatment for ITP is administered prior to administering one or more doses of the hFcRn antagonist.

12. The method of claim 7 , wherein the corticosteroid is selected from the group consisting of prednisone, methylprednisolone, and dexamethasone.

13. The method of claim 1 , wherein the human subject achieves a platelet count of >50×10 9 /L for at least 4 weeks.

14. The method of claim 1 , wherein the human subject achieves a platelet count of >50×10 9 /L for at least 4 of 6 consecutive weeks.

Assignments (3)
CHANGE OF NAME Recorded Apr 8, 2022
From: ARGENX BVBA
To: ARGENX BV
Reel/Frame 059539/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2019
From: DE HAARD, HANS; ULRICHTS, PETER; LEUPIN, NICOLAS; DREIER, TORSTEN; VAN BRAGT, TONKE; ENRIQUEZ, JAVIER
To: ARGENX BVBA
Reel/Frame 050932/0861 →
EMPLOYMENT AGREEMENT Recorded Nov 6, 2019
From: COUSIN, THIERRY
To: ARGENX BVBA
Reel/Frame 050942/0644 →
Continuity (4)
Provisional Application 62732414 · Sep 17, 2018
Provisional Application 62731947 · Sep 16, 2018
Provisional Application 62682805 · Jun 8, 2018
Related Publication 20200024344A1 · Jan 23, 2020
References Cited (400)
US 5326856A · Coughlin et al. · 1994 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5677425A · Bodmer et al. · 1997 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5885573A · Bluestone et al. · 1999 [cited by applicant]
US 6121022A · Presta et al. · 2000 [cited by applicant]
US 6165745A · Ward et al. · 2000 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6277375B1 · Ward · 2001 [cited by applicant]
US 6528624B1 · Idusogie et al. · 2003 [cited by applicant]
US 6737056B1 · Presta et al. · 2004 [cited by applicant]
US 6795661B2 · Dall'Acqua et al. · 2004 [cited by applicant]
US 6821505B2 · Ward · 2004 [cited by applicant]
US 6992234B2 · Roopenian et al. · 2006 [cited by applicant]
US 7083784B2 · Dall'Acqua et al. · 2006 [cited by applicant]
US 7183387B1 · Presta · 2007 [cited by applicant]
US 7670600B2 · Dall'Acqua et al. · 2010 [cited by applicant]
US 7683784B2 · Nagai et al. · 2010 [cited by applicant]
US 7704497B2 · Dall'Acqua et al. · 2010 [cited by applicant]
US 8012476B2 · Dall'Acqua et al. · 2011 [cited by applicant]
US 8021856B2 · Umaña et al. · 2011 [cited by applicant]
US 8067232B2 · Kanda · 2011 [cited by applicant]
US 8101186B2 · Mezo et al. · 2012 [cited by applicant]
US 8163881B2 · Ober et al. · 2012 [cited by applicant]
US 8195661B2 · Asawaree · 2012 [cited by applicant]
US 8216805B2 · Carter et al. · 2012 [cited by applicant]
US 8273351B2 · Tenhoor et al. · 2012 [cited by applicant]
US 8323962B2 · Dall'Acqua et al. · 2012 [cited by applicant]
US 8475792B2 · Dall'Acqua et al. · 2013 [cited by applicant]
US 8680237B2 · Strome et al. · 2014 [cited by applicant]
US 8795661B2 · Dall'Acqua et al. · 2014 [cited by applicant]
US 8815246B2 · Tenhoor et al. · 2014 [cited by applicant]
US 8834871B2 · Ober · 2014 [cited by applicant]
US 9260520B2 · Tenhoor et al. · 2016 [cited by applicant]
US 10316073B2 · Ulrichts · 2019 [cited by applicant]
US 11505585B2 · Ulrichts et al. · 2022 [cited by applicant]
US 11591388B2 · Borgions et al. · 2023 [cited by applicant]
US 20040002587A1 · Watkins et al. · 2004 [cited by applicant]
US 20040010124A1 · Johnson et al. · 2004 [cited by applicant]
US 20040047862A1 · Lazarus et al. · 2004 [cited by applicant]
US 20040265321A1 · Johnson et al. · 2004 [cited by applicant]
US 20050053598A1 · Burke et al. · 2005 [cited by applicant]
US 20060210557A1 · Luisi · 2006 [cited by examiner]
US 20070041907A1 · Ober · 2007 [cited by applicant]
US 20070092507A1 · Balthasar et al. · 2007 [cited by applicant]
US 20090252729A1 · Farrington et al. · 2009 [cited by applicant]
US 20110066111A1 · Teschner et al. · 2011 [cited by applicant]
US 20110081345A1 · Moore · 2011 [cited by applicant]
US 20110243966A1 · Farrington et al. · 2011 [cited by applicant]
US 20120219551A1 · Johnson · 2012 [cited by applicant]
US 20130142802A1 · Chang et al. · 2013 [cited by applicant]
US 20140302028A1 · Zha et al. · 2014 [cited by applicant]
US 20150218239A1 · Ulrichts · 2015 [cited by examiner]
US 20160264669A1 · Ulrichts et al. · 2016 [cited by applicant]
US 20190194277A1 · de Haard et al. · 2019 [cited by applicant]
US 20210236596A1 · Verheesen et al. · 2021 [cited by applicant]
US 20220275035A1 · Ulrichts et al. · 2022 [cited by applicant]
US 20230357382A1 · Borgions et al. · 2023 [cited by applicant]
EP 0227110A2 · 1987 [cited by applicant]
EP 0904107B1 · 1999 [cited by applicant]
EP 1355919B1 · 2010 [cited by applicant]
EP 1896503B1 · 2014 [cited by applicant]
JP 2013507128A · 2013 [cited by applicant]
WO WO1994029351A2 · 1994 [cited by applicant]
WO WO1996022024A1 · 1996 [cited by applicant]
WO WO1997034631A1 · 1997 [cited by applicant]
WO WO1999004813A1 · 1999 [cited by applicant]
WO WO1999058572A1 · 1999 [cited by applicant]
WO WO2000042072A2 · 2000 [cited by applicant]
WO WO2001058957A2 · 2001 [cited by applicant]
WO WO2002043658A2 · 2002 [cited by applicant]
WO WO2002060919A2 · 2002 [cited by applicant]
WO WO2004016750A2 · 2004 [cited by applicant]
WO WO2004029207A2 · 2004 [cited by applicant]
WO WO2004035752A2 · 2004 [cited by applicant]
WO WO2004063343A2 · 2004 [cited by applicant]
WO WO2004063351A2 · 2004 [cited by applicant]
WO WO2004099249A2 · 2004 [cited by applicant]
WO WO2005040217A2 · 2005 [cited by applicant]
WO WO2006118772A2 · 2006 [cited by applicant]
WO WO2006130834A2 · 2006 [cited by applicant]
WO WO2007098420A2 · 2007 [cited by applicant]
WO WO2009100105A2 · 2009 [cited by applicant]
WO WO2009131702A2 · 2009 [cited by applicant]
WO WO2010014909A1 · 2010 [cited by applicant]
WO WO2010106180A2 · 2010 [cited by applicant]
WO WO2010111254A1 · 2010 [cited by applicant]
WO WO2011044368A1 · 2011 [cited by applicant]
WO WO2011080209A2 · 2011 [cited by applicant]
WO WO2012167039A1 · 2012 [cited by applicant]
WO WO2013000702A1 · 2013 [cited by applicant]
WO WO2013063186A2 · 2013 [cited by applicant]
WO WO2013074598A1 · 2013 [cited by applicant]
WO WO2013100702A1 · 2013 [cited by applicant]
WO 2013166604A1 · 2013 [cited by applicant]
WO WO2014008391A1 · 2014 [cited by applicant]
WO WO2014019727A1 · 2014 [cited by applicant]
WO 2014140366A1 · 2014 [cited by applicant]
WO WO2014204280A1 · 2014 [cited by applicant]
WO 2015071330A1 · 2015 [cited by applicant]
WO 2015073721A1 · 2015 [cited by applicant]
WO WO2015081073A2 · 2015 [cited by applicant]
WO WO2015100299A1 · 2015 [cited by applicant]
WO WO2016042083A1 · 2016 [cited by applicant]
WO WO2016123521A2 · 2016 [cited by applicant]
WO WO2016142782A1 · 2016 [cited by applicant]
WO WO2016180765A1 · 2016 [cited by applicant]
WO WO2016183352A1 · 2016 [cited by applicant]
WO WO2017012959A1 · 2017 [cited by applicant]
WO WO2017121330A1 · 2017 [cited by applicant]
WO 2017189959A1 · 2017 [cited by applicant]
WO 2018023136A1 · 2018 [cited by applicant]
WO WO2018083122A1 · 2018 [cited by applicant]
WO WO2019110823A1 · 2019 [cited by applicant]
WO WO2019118791A1 · 2019 [cited by applicant]
WO WO2019234713A2 · 2019 [cited by applicant]
WO 2020078905A1 · 2020 [cited by applicant]
WO WO2020097099A1 · 2020 [cited by applicant]
WO 2020227515A1 · 2020 [cited by applicant]
WO WO2020236695A1 · 2020 [cited by applicant]
WO 2020245420A1 · 2020 [cited by applicant]
WO 2021022249A1 · 2021 [cited by applicant]
WO 2020245420A9 · 2021 [cited by applicant]
WO 2021140202A1 · 2021 [cited by applicant]
WO 2021216756A1 · 2021 [cited by applicant]
WO 2022098955A1 · 2022 [cited by applicant]
WO 2023012515A2 · 2023 [cited by applicant]
WO 2023135321A1 · 2023 [cited by applicant]
WO 2023156614A1 · 2023 [cited by applicant]
WO 2023209036A1 · 2023 [cited by applicant]
WO 2023242361A1 · 2023 [cited by applicant]
WO 2023242362A1 · 2023 [cited by applicant]
WO 2023242371A1 · 2023 [cited by applicant]
WO 2023242372A1 · 2023 [cited by applicant]
WO 2024100453A1 · 2024 [cited by applicant]
WO 2024100455A1 · 2024 [cited by applicant]
WO 2024105445A2 · 2024 [cited by applicant]
WO 2024147074A1 · 2024 [cited by applicant]
WO 2024150073A1 · 2024 [cited by applicant]
Newland, Adrian C et al. American journal of hematology vol. 95,2 (2020): 178-187. doi:10.1002/ajh.25680 (Year: 2020). [cited by examiner]
Khan, Ayesha M et al. P & T: a peer-reviewed journal for formulary management vol. 42, 12 (2017): 756-763 (Year: 2017). [cited by examiner]
Janeway, Charles A. “Immunobiology: the Immune System in Health and Disease.” 2005 (Year: 2005). [cited by examiner]
Robak, Tadeusz, et al. Blood 130.Supplement 1 (2017): 15-15 (Year: 2017). [cited by examiner]
Bussel, James B., et al. New England Journal of Medicine 357.22 (2007): 2237-2247 (Year: 2007). [cited by examiner]
(Robak, Tadeusz, et al Hematology 15.5 (2010): 351-359) (Year: 2010). [cited by examiner]
Michael F. Halle, Pharmaceutical Technology, Advanstar Communications Inc. Oct. 2, 2007, vol. 31, Issue 10 (Year: 2007). [cited by examiner]
Broome C. et al, “Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia: Advance SC, a Global Phase 3 Clinical Trial in Progress” [abstract]. Res Pract Thromb Haemo… [cited by examiner]
Abdiche et al. (2015) “The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity,” mAbs, 7(2):331-343. [cited by applicant]
Akilesh et al. (2004) “The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease,” J. Clin. Invest. 113(9):1328-1333. [cited by applicant]
Alegre et al. (1994) “A Non-Activating “Humanized” Anti-CD3 Monoclonal Antibody Retains Immunosuppressive Properties in Vivo,” Transplantation, 57(11):1537-1543. [cited by applicant]
Alipour-Faz et al. (2017) “A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients,” Acta Neurol Belg, 117:245-249. [cited by applicant]
Andersen et al. (2012) “Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor,” Nat. Commun. 3:610. pp. 1-9. [cited by applicant]
Anonymous (2016) “argenx announces initial results from Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers—Argenx,” 1 pg. [cited by applicant]
Argen-X “ARGX-113,” http://www.argen-x.com. Accessible on the Internet at URL: http://www.argen-x.com/en-GB/content/argx-113/22. [Last Accessed Jul. 5, 2017]. [cited by applicant]
Argen-X (Oct. 2013) “An Emerging Antibody Force: Company Presentation,” Presentation Slides. [cited by applicant]
Argen-X (Oct. 2013) “ARGX-113: Development Opportunity in Autoimmunity,” Presentation Slides. [cited by applicant]
Argen-X N.V. (Apr. 24, 2014) “arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders,” Press Release. arGEN-X. Accessible on the Internet at URL: http://www.argen-x.com/en-GB/news-internal/argen… [cited by applicant]
Argen-X N.V. (Aug. 19, 2014) “arGEN-X announces positive preclinical results for ARGX-113,” Press Release. Euronext. Accessible on the Internet at URL: https://www.euronext.com/nl/node/506652. [Last Accessed Aug. 1, 201… [cited by applicant]
Argen-X N.V. (Jun. 20, 2014) Prospectus for Public Offering of arGEN-X N.V. [cited by applicant]
Armour et al. (1999) “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,” Eur. J. Immunol. 29:2613-2624. [cited by applicant]
Ballow (1991) “Mechanism of action of IVIG therapy and potential uses in autoimmune connective tissue diseases,” Cancer 68:1430-1436. [cited by applicant]
Barth et al. (2011) “Comparison of IVIg and Plex in patients with myasthenia gravis,” Neurology. 76(23):2017-2023. [cited by applicant]
Blanchette et al. (1984) “Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenia purpura,” Transfusion. 24(5):388-394. [cited by applicant]
Burns (2012) “Of Mice and Children: Lessons From a Kawasaki Mouse Model,” Circulation. 125:1480-1481. [cited by applicant]
Burns et al. (2010) “History of outcome measures for myasthenia gravis,” Muscle Nerve. 42(1):5-13. [cited by applicant]
Challa (2013) “Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis,” mAbs, 5(5):655-659. [cited by applicant]
Chaudhury et al. (2003) “The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan,” J. Exp. Med. 197(3):315-322. [cited by applicant]
Cipriani et al. (2009) “Met as a target for treatment of chest tumor,” Lung Cancer. 63(2):169-179. [cited by applicant]
Clarkson et al. (1986) “Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcgamma-Receptor Antibody,” New England Journal of Medicine. 314(9):1236-1239. [cited by applicant]
Coetzee et al. (2000) “The Effect of Monoclonal Anti-human-platelet Antibodies on Platelet Kinetics in a Baboon Model: IgG Subclass Dependency,” Thromb. Haemost. 83:148-156. [cited by applicant]
Crow et al. (2008) “The Mechanisms of Action of Intravenous Immunoglobulin and Polyclonal Anti-D Immunoglobulin in the Amelioration of Immune Thrombocytopenia Purpura: What Do We Really Know?” Transfusion Medicine Revie… [cited by applicant]
Crow et al. (2011) “The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody-mediated amelioration of murine immune thrombocytopenia,” Blood. 118:6403-6406. [cited by applicant]
Darabi et al. (2006) “Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature,” Transfusion. 46(5):741-753. [cited by applicant]
Debre et al. (1993) “Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenia purpura,” Lancet. 342(8877):945-949. [cited by applicant]
Deng et al. (2007) “Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia,” J. Pharm. Sci. 96(6):1625-1637. [cited by applicant]
Duncan et al. (1988) “Localization of the binding site for the human high-affinity Fc receptor on IgG,” Nature, 332:563-564. [cited by applicant]
Edelman et al. (1969) “The covalent structure of an entire gammaG immunoglobulin molecule,” the Journal of Immunology, 63:5335-5342. [cited by applicant]
El-Salem et al. (2014) “Treatment of MuSK-Associated Myasthenia Gravis,” Curr. Treat. Options Neurol., 16:283, 17 pages. [cited by applicant]
Eymard et al. (2009) “[Antibodies in myasthenia gravis],” Rev. Neurol. (Paris). 165(2):137-143. [cited by applicant]
Federico et al. (2000) “Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study,” Neurology. 55:1256-1262. [cited by applicant]
Flaherty et al. (Oct. 24, 2011) “Nonclinical evaluation of GMA161—an antihuman CD16 (Form) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice,” Toxicological Sciences. 125(1):299-309. [cited by applicant]
Frusho et al. (1984) “High-dose intravenous gammaglobulin for Kawasaki disease,” Lancet. 2:1055-1058. [cited by applicant]
Gan et al. (2009) “Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery,” Traffic. 10:600-614. [cited by applicant]
Garcia et al. (2001) “Kinetics and thermodynamics of T cell receptor-autoantigen interactions in murine experimental autoimmune encephalomyelitis,” Proc. Natl. Acad. Sci. USA. 98:6818-6823. [cited by applicant]
Genbank Database [online] (Jul. 2, 2016) “ [cited by applicant]
Ghetie et al. (1996) “Abnormally short serum half lives of IgGs in beta2-microglobulin deficient mice,” Eur. J. Immunol. 26:690-696. [cited by applicant]
Ghetie et al. (1997) “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nature Biotech. 15:637-640. [cited by applicant]
Ghetie et al. (2002) “Transcytosis and catabolismof antibody,” Immunol. Res. 25(2):97-113. [cited by applicant]
Gilhus et al. (2011) “Myasthenia Gravis: a Review of Available Treatment Approaches,” Autoimmune Diseases, Article ID 847393, 6 pages. [cited by applicant]
Grau (Sep. 21, 2011) “IgG core a-fucosylation and its impact on FcγRllla binding,” Roche Glycart AG. In; MipTec 2011, Basel, Switzerland. [cited by applicant]
Grevys et al. (Apr. 22, 2015) “Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions,” J Immunol. 194(11):5497-5508. [cited by applicant]
Guptill et al. (Aug. 11, 2016) “Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis,” Autoimmunity. 49(7):472-479. [cited by applicant]
Hansen et al. (2002) “Intravenous Immunoglobulin Mediates an Increase in Anti-Platelet Antibody Clearance via the FcRn Receptor,” Thromb. Haemost. 88:898-899. [cited by applicant]
Hanson (2014) “The role of the immunoglobulin G1 Fc N-glycan in FcγRllla affinity,” Thesis for partial fulfillment of the degree of Master of Science. Iowa State University. Paper 14135. [cited by applicant]
Howard et al. (Apr. 30, 2013) “A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis,” Muscle Nerve. 48(1):76-84. [cited by applicant]
Huang et al. (2005) “The central residues of a T cell receptor sequence motif are key determinants of autoantigen recognition in murine experimental autoimmune encephalomyelitis,” Eur. J. Immunol. 35:299-304. [cited by applicant]
Hutchins et al. (1995) “Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma4 variant of Campath-1H,” Proc. Natl. Acad. Sci., USA, 92:11980-11984. [cited by applicant]
Idusogie et al. (2000) “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc,” J. Immunol., 164:4178-4184. [cited by applicant]
Idusogie et al. (2001) “Engineered Antibodies with Increased Activity to Recruit Complement,” J. Immunol., 166:2571-2575. [cited by applicant]
Imbach et al. (1981) “High-dose intravenous gammaglobulin for idiopathic thrombocytopenia purpura in childhood,” The Lancet, 1228-1231. [cited by applicant]
Imbach et al. (1985) “Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenia purpura in childhood,” The Lancet, 464-468. [cited by applicant]
Imbach et al. (2009) “Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders,” Vox Sanguinis, 10 pages. [cited by applicant]
Imbach, Paul (2012) “Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases,” Swiss Medical Weekly, 10 pages. [cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/068399, issued Mar. 10, 2015. [cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2014/072087, issued Jun. 28, 2016. [cited by applicant]
International Search Report and Written Opinion corresponding to International Patent Application PCT/EP2017/077966, mailed Jan. 29, 2018. [cited by applicant]
International Search Report corresponding to International Patent Application No. PCT/EP2013/068399, mailed Apr. 9, 2014. [cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/072087, mailed May 12, 2015. [cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2018/084034, mailed Feb. 18, 2019. [cited by applicant]
Jacob et al. (2012) “Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis,” Arch Neurol., 69(8):994-1001. [cited by applicant]
Jain et al. (Aug. 20, 2012) “Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenia purpura in mice,” Arthritis Research & Therapy 14:R192.… [cited by applicant]
Jefferis et al. (1995) “Recognition sites on human IgG for Fcgamma receptors: the role of glycosylation,” Immunology Letters, 44:111-117. [cited by applicant]
Jefferis et al. (1996) “Modulation of Fc(gamma)R and human complement activation by IgG3-core oligosaccharide interactions,” Immunol. Lett. 54:101-104. [cited by applicant]
Jefferis et al. (2002) “Interaction sites on human IgG-Fc for FcgammaR: current models,” Immunology Letters, 82:57-65. [cited by applicant]
Junghans (1997) “Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolismfor IgG,” Immunologic Research. 16(1):29-57. [cited by applicant]
Junghans et al. (1996) “The protection receptor for IgG catabolismis the beta2-microglobulin-containing neonatal intestinal transport receptor,” Proc. Natl. Acad. Sci. USA. 93:5512-5516. [cited by applicant]
Kanda et al. (2006) “Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types,” Glycobiol. 17(1):1… [cited by applicant]
Kim et al. (1999) “Mapping of the site on human IgG1 for binding of the MHC class I related receptor, FcRn,” Eur. J. Immunol. 29:2819-2825. [cited by applicant]
Law et al. (1997) “High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenia purpura,” N. Engl. J. Med. 336:1494-1498. [cited by applicant]
Li et al. (2005) “Complete FcRn dependence for intravenous lg therapy in autoimmune skin blistering diseases,” J. Clin. Invest. 115(12):3440-3450. [cited by applicant]
Liu et al. (2007) “Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade,” J. Immunol. 178(8):5390-5398. [cited by applicant]
Liu et al. (2009) “Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late-Onset Myasthenia Gravis,” Therap… [cited by applicant]
Low et al. (2009) “Inhibitors of the FcRn:IgG Protein-Protein Interaction,” AAPS Journal. 11(3):432-434. [cited by applicant]
Lund et al. (1991) “Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG,” J. Immunol. 147:2657-2662. [cited by applicant]
Lund et al. (1992) “Multiple binding sites on the CH2 Domain of IgG for Mouse FcgammaRII,” Molecular Immunology, 29(1):53-59. [cited by applicant]
Lund et al. (1995) “Oligosaccharide-protein interactions in IgG can modulate recognition by Fcgamma receptors,” The FASEB Journal 9:115-119. [cited by applicant]
Lund et al. (1996) “Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains,” J. Immunol.… [cited by applicant]
Lutterbach et al. (2007) “Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival,” Cancer Research. 67(5):2081-2088. [cited by applicant]
MacCallum et al. (1996) “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 262:732-745. [cited by applicant]
Martin et al. (2001) “Crystal Structure at 2.8 A of an FcRn/Heterodimeric Fc Complex Mechanism of pH-Dependent Binding,” Molecular Cell, 7:867-877. [cited by applicant]
Massachusetts General Hospital (Dec. 10, 2012) “Suppremol's Sm101 shows a sustained clinical activity and a favorable safety profile in primary immune thrombocytopenia (ITP) patients,” Press Release. Evaluate Ltd. [cited by applicant]
Medesan et al. (1997) “Delineation of the amino acid residues involved in transcytosis and catabolism of mouse IgG,” J. Immunol. 158:2211-2217. [cited by applicant]
Mendell et al. (2001) “Randomized controlled trial of IVlg in untreated chronic inflammatory demyelinating polyradiculoneuropathy,” Neurology. 56:445-449. [cited by applicant]
Meriggioli et al. (2009) “Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity,” Lancet Neurol. 8:475-490. [cited by applicant]
Mezo et al. (2008) “Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn,” Proc. Natl. Acad. Sci. USA. 105(7):2337-2342. [cited by applicant]
Mi et al. (2008) “Targeting the neonatal Fc receptor for antigen delivery using engineered Fc fragments,” J. Immunol. 181:7550-7561. [cited by applicant]
Mohamed et al. (Jan. 7, 2013) “Massive intravascular haemolysis after high dose intravenous immunoglobulin therapy,” British Journal of Haematology. 160:570. [cited by applicant]
Montoyo et al. (2009) “Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice,” Proc. Natl. Acad. Sci. USA. 106:2788-2793. [cited by applicant]
Morea et al. (2000) “Antibody Modeling: Implications for Engineering and Design,” Methods, 20:267-279. [cited by applicant]
Newburger et al. (2004) “Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: a Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Car… [cited by applicant]
Newland et al. (1983) “High-dose intravenous IgG in adults with autoimmune thrombocytopenia,” the Lancet, 84-87. [cited by applicant]
Nieswandt et al. (1999) “Acute systemic reaction and lung alterations induced by an antiplatelet integrin gpllb/llla antibody in mice,” Blood. 94:684-693. [cited by applicant]
Niknami et al. (Jun. 2013) “Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis),” J. Peripher. Nerv. Syst. 18(2):141-52. [cited by applicant]
Ober et al. (2004) “Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level,” Proc. Natl. Acad. Sci. USA. 101:11076-11081. [cited by applicant]
Ober et al. (2004) “Visualizing the site and dynamics of IgG salvage by the MHC Class I-related receptor, FcRn,” J. Immunol. 172:2021-2029. [cited by applicant]
Oshima et al. (1998) “Characterization of murine CD70 by molecular cloning and mAb,” Int. Immunol. 10(4):517-526. [cited by applicant]
Patel et al. (2011) “Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model,” J. Immunol. 187(2):1015-1022. [cited by applicant]
Pevzner et al. (2011) “Anti-LRP4 autoantibodies in AChR-and MuSK-antibody-negative myasthenia gravis,” J. Neurol., 9 pages. [cited by applicant]
Prabhat et al. (2007) “Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy,” Proc. Natl. Acad. Sci. USA. 104:5889-5894. [cited by applicant]
Presta et al. (2002) “Engineering therapeutic antibodies for improved function,” Biochemical Society Transactions, 30(4):487-490. [cited by applicant]
Reddy et al. (2000) “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4,” J. Immunol., 164:1925-1933. [cited by applicant]
Roopenian et al. (2003) “The MHC class l-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs,” J. Immunology. 170:3528-3533. [cited by applicant]
Roopenian et al. (2007) “FcRn: the neonatal Fc receptor comes of age,” Nat. Rev. Immunol. 7(9):715-725. [cited by applicant]
Roux et al. (1998) “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to Form Small Immune Complexes: a Role for Flexibility and Geometry,” the Journal of Immunology, 4083-4090. [cited by applicant]
Schwab et al. (Mar. 2013) “Intravenous immunoglobulin therapy: how does IgG modulate the immune system?” Nat. Rev. Immunol. 176(13). [cited by applicant]
Seidling et al. (2013) “Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events,” Acta Derm Venereol. 93:34… [cited by applicant]
Semple (2010) “Animal models of immune thrombocytopenia (ITP),” Annals of Hematology. 89:37-44. [cited by applicant]
Sesarman et al. (2010) “The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases,” Cell. Mol. Life Sci. 67(15):2533-2550. [cited by applicant]
Sewell: Ed. (Jan. 22, 2010) First National Immunoglobulin Database Report. Department of Health. [cited by applicant]
Shelton (1999) “Acquired myasthenia gravis: what we have learned from experimental and spontaneous animal models,” Veterinary Immunology and Immunopathology. 69:239-249. [cited by applicant]
Shields et al. (2001) “High Resolution Mapping of the Binding Site on Human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcgammaR,” the Journal of Biolog… [cited by applicant]
Sockolosky et al. (2015) “The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy,” Advanced Drug Delivery Reviews, 91:109-124. [cited by applicant]
Soliven (2012) “Autoimmune neuropathies: insights from animal models,” Journal of the Peripheral Nervous System. 17:28-33. [cited by applicant]
Sorde et al. (2017) “Massive immune response against IVIg interferes with response against other antigens in mice: a new mode of action?,” PLoS One, 12(10):e0186046, 15 pages. [cited by applicant]
Stamos et al. (2004) “Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor,” Embo J. 23(12):2325-2335. [cited by applicant]
Swiercz et al. (May 27, 2014) “Use of Fc-engineered antibodies as clearing agents to increase contrast during Pet,” J. Nucl. Med. 55:1204-1207. [cited by applicant]
Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America, et al. (2000) “Myasthenia gravis,” Neurology, 55:16-23. [cited by applicant]
Tramontano et al. (1990) “Framework Residue 71 is a Major Determinant of the Position and Conformation of the Second Hypervariable Region in the VH Domains of Immunoglobulins,” J. Mol. Biol., 215:175-182. [cited by applicant]
Ulrichts et al. (2018) “Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans,” J. Clin. Invest., 16 pages. [cited by applicant]
Ulrichts et al. (May 2017) “ARGX-113: Towards a Safe and Selective Elimination of Pathogenic Autoantibodies,” 13th International Conference on Myasthenia Gravis and Related Disorders, May 15-17, 2017. New York, New York… [cited by applicant]
Vaccaro et al. (2005) “Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels,” Nat. Biotechnol. 23(10):1283-1288. [cited by applicant]
Vaccaro et al. (2006) “Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies” Proc. Natl. Acad. Sci. USA. 103(49):18709-18714. [cited by applicant]
Van Der Meche et al. (1992) “A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group,” N. Engl. J. Med. 326:1123-1129. [cited by applicant]
Wani et al. (2006) “Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene,” Proc. Natl. Acad. Sci. USA. 103(13):5084-5989. [cited by applicant]
Woods et al. (1984) “Autoantibodies against platelet glycoprotein lb in patients with chronic immune thrombocytopenia purpura,” Blood. 64:156-160. [cited by applicant]
Written Opinion corresponding to International Patent Application No. PCT/EP2013/068399, mailed Apr. 14, 2014. [cited by applicant]
Xu et al. (2000) “In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies,” Cellular Immunology, 200:16-26. [cited by applicant]
Yang et al., (2011) “Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China,” Journal of Neurological Sciences, 301:71-76, 2011. [cited by applicant]
Ying et al. (2012) “Soluble Monomeric IgG1 Fc,” the Journal of Biological Chemistry, 287(23):19399-19408. [cited by applicant]
Ying et al. (2013) “Engineered Soluble Monomeric IgG1 CH3 Domain,” the Journal of Biological Chemistry, 288 (35):25154-25164. [cited by applicant]
Zhang et al. (2012) “Autoantibodies to Lipoprotein-Related Protein in Patients With Double-Seronegative Myasthenia Gravis,” Arch Neurol, 69(4):445-451. [cited by applicant]
Zhou et al. (2005) “Conferring the binding properties of the mouse MHC Class I related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis,” J. Mol. Biol. 345:1071-1081. [cited by applicant]
Zhou et al. (2003) “Generation of mutated variants of the human form of the MHC class l-related receptor, FcRn, with increased affinity for mouse immunoglobulin G,” J. Mol. Biol. 332:901-913. [cited by applicant]
Zinman et al. (2007) “IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial,” Neurology 68:837-841. [cited by applicant]
Bussel et al., “Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP) : Romiplostim in Pediatric ITP” Pediatric Blood and Cancer, Feb. 1, 2015, vol. 62, No… [cited by applicant]
Dick Jr. et al., “C-Terminal Lysine Variants in Fully Human Monoclonal Antibodies: Investigation of Test Methods and Possible Causes”, Biotechnology and Bioengineering, 2008, vol. 100, No. 6, pp. 1132-1143. [cited by applicant]
Eddleston et al., “Blockade of the Neonatal Fe Receptor (FcRn) Represents an Effective Mechanism for the Removal of Pathogenic Autoantibodies in Primary Immune Thrombocytopenia”, Database Biosis [Online] Biosciences Inf… [cited by applicant]
Howard et al., “Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis”, Neurology, 2019, vol. 92, No. 23, pp. 1-8. [cited by applicant]
Swiss Webster Mice, by Taconic, Aug. 23, 2018, pp. 1-7. [cited by applicant]
U.S. Appl. No. 16/893,863, filed Jun. 5, 2020, Filip Borgions. [cited by applicant]
Anonymous: “A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients with ITP”, Apr. 6, 2017, pp. 1-7. [cited by applicant]
Bussel et al., “A Randomized, Double-Blind Study of Romiplostim to Determine its Safety and Efficacy in Children with Immune Thrombocytopenia”, Blood, vol. 118, No. 1, Jul. 7, 2011, pp. 28-36. [cited by applicant]
De Haard et al., “Advancing ARGX-113 and ARGX-110 to Clinical Proof of Concept”, Dec. 4, 2016, pp. 1-575. [cited by applicant]
International Search Report and Written Opinion in related PCT Application No. PCT/IB2019/054786, mailed Dec. 18, 2109 (27 pages). [cited by applicant]
Ulrichts et al., “ARGX-113, a Novel Fc-Based Approach for Antibody-Induced Pathologies Such as Primary Immune Thrombocytopenia”, Blood, vol. 128, No. 22, Dec. 2016, p. 4919, 58 [cited by applicant]
U.S. Appl. No. 14/580,771, 2015/0218239, 10,316,073, filed Dec. 23, 2014, Aug. 6, 2015, Jun. 11, 2019, Peter Ulrichts. [cited by applicant]
U.S. Appl. No. 16/893,863, 2020/0399363, filed Jun. 5, 2020, Dec. 24, 2020, Filip Borgions. [cited by applicant]
U.S. Appl. No. 16/435,166, 2020/0024344, filed Jun. 7, 2019, Jan. 23, 2020, Hans de Haard. [cited by applicant]
PCT/IB2019/054786, WO 2019/234713, filed Jun. 7, 2019, Dec. 12, 2019, Hans de Haard. [cited by applicant]
U.S. Appl. No. 17/144,481, 2021/0236596, filed Jan. 8, 2021, Aug. 5, 2021, Peter Verheesen. [cited by applicant]
“Anthony et al., Apr. 18, 2008, Science, 320(5874): 373-376”, Document D14 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020.O. [cited by applicant]
“ArGEN-X advances ARGX-113 into preclinical development for autoimmune disorders, Apr. 24, 2014”, Document D38 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May … [cited by applicant]
“ArGEN-X Announces Positive Preclinical Results for ARGX-113, Aug. 19, 2014”, Document D39 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Assignment submission for U.S. Appl. No. 61/920,547 confirming change of legal form of arGEN-X B.V. to arGEN-X N.V. on May 28, 2014”, Document D30 submitted with Notice of Opposition for European Patent No. 3087095 (Ap… [cited by applicant]
“Auxiliary Request 1—Annotated Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages. [cited by applicant]
“Auxiliary Request 1—Clean Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages. [cited by applicant]
“Auxiliary Request 2—Annotated Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages. [cited by applicant]
“Auxiliary Request 2—Clean Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 4 pages. [cited by applicant]
“Blumberg & Lencer, Oct. 2005, Nat Biotechnol., 23(10): 1232-1234”, Document D03 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Bruhns et al., Apr. 2003, Immunity, 18(4): 573-571”, Document D16 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Brych et al., Feb. 2010, J Pharm Sci., 99(2): 764-781”, Document D37 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Carter, May 2006, Nat Rev immunol., 6(5): 343-357”, Document D22 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Challa et al., Sep.-Oct. 2013, MAbs, 5(5): 655-659”, Document D10 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Corrected Filing Receipt for U.S. Appl. No. 61/920,547 dated Apr. 16, 2015”, Document D27 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Corrected Filing Receipt for U.S. Appl. No. 61/920,547 dated Apr. 18, 2014”, Document D26 submitted with to Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Cover Letter to the European Patent Office” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 1 page. [cited by applicant]
“Dall'Acqua et al., Nov. 1, 2002, J Immunol., 169(9): 5171-5180”, Document D21 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Debre et al., Oct. 16, 1993, Lancet, 342: 945-949”, Document D12 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Declaration of Pieter Spuijbroek”, Document D42 submitted with Reply to Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages. [cited by applicant]
“Dimitrov, Jan.-Feb. 2009, MAbs, 1(1): 26-28”, Document D20 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“EP 1896503 Amended Claims and Response submitted Feb. 23, 2014 during prosecution of the application which led to grant of D1”, Document D02a submitted with Notice of Opposition for European Patent No. 3087095 (Applica… [cited by applicant]
“EP 1896503 B1 dated Oct. 29, 2014”, Document D01 submitted with Reply to Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“EP 3087095 B1 dated Aug. 7, 2019” submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Filing Receipt for U.S. Appl. No. 61/920,547 dated Jan. 21, 2014”, Document D25 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Gan et al., May 2009, Traffic, 10(5): 600-614”, Document D08 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Goh and Ng, Sep. 2018, Crit Rev Biotechnol., 38(6): 851-867”, Document D19 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Gómez-Guerrero et al., Feb. 15, 2000, J Immunol., 164(4): 2092-2101”, Document D15 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Inventor Assignment of U.S. Appl. No. 61/920,547 to arGEN-X B.V. executed Oct. 31, 2014 and Nov. 4, 2014”, Document D29 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), … [cited by applicant]
“Inventor Assignment of U.S. Appl. No. 61/920,547 to The Board of Regents of the University of Texas System executed Dec. 23, 2014”, Document D28 submitted with Notice of Opposition for European Patent No. 3087095 (Appl… [cited by applicant]
“Jefferis and Lefranc, July-Aug. 2009, MAbs, 1(4): 332-338”, Document D35 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Kaneko et al., Aug. 4, 2006, Science, 313(5787): 670-673”, Document D17 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Main Request—Annotated Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages. [cited by applicant]
“Main Request—Clean Version” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 5 pages. [cited by applicant]
“Notice of Opposition” to European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020, 47 pages. [cited by applicant]
“Online Filing Acknowledgement for Notice of Opposition” for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020, 3 pages. [cited by applicant]
“Online Filing Acknowledgement for Reply to Notice of Opposition” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 2 pages. [cited by applicant]
“Patel et al., Jul. 15, 2011, J Immunol., 187(2): 1015-1022”, Document D09 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“PCT Request for as filed for PCT/US2014/072087 on Dec. 23, 2014”, Document D34 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Proof of Employment for Inventor/Applicant Sally Ward”, Document D40 submitted with Reply to Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 1 page. [cited by applicant]
“Putnam and Miyake, Apr. 1958, J Biol Chem, 231(2):671-684”, Document D33 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Pyzik et al., Jul. 10, 2019, Front Immunol., 10: 1540”, Document D31 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Reply to Notice of Opposition” for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 35 pages,. [cited by applicant]
“Rule 90101 of the Rules and Regulations of the Board of Regents of the University of Texas System governing intellectual property” dated Feb. 27, 2012, submitted with Reply to Notice of Opposition for European Patent N… [cited by applicant]
“Samuelsson et al., Jan. 19, 2001, Science, 291(5503): 484-486”, Document D13 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Schwab and Nimmerjahn, Mar. 2013, Nat Rev Immunol., 13(3): 176-189”, Document D11 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Sequence alignment of SEQ ID No. 22 from D6 and SEQ ID Nos. 1, 2, and 3 from the Patent”, Document D32 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Sequence Alignment of SEQ ID Nos. 1-3 from Patent and corresponding portion of Uniprot ID: P01857”, Document D24 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated M… [cited by applicant]
“Shields et al., Mar. 2, 2001, J Biol Chem., 276(9): 6591-6604”, Document D23 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Ulrichts et al., Oct. 1, 2018, J Clin Invest., 128(10): 4372-4386”, Document D18 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“UniProtKB—P01857 (IGHG1_HUMAN)”submitted with Reply to Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated Oct. 28, 2020, 6 pages. [cited by applicant]
“Vacarro et al., Dec. 2006, Proc Natl Acad Sci USA, 103(49): 18709-18714”, Document D07 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Vaccarro et al., Oct. 2005, Nat Biotechnol., 23(10): 1283-1288”, Document D04 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Ward & Ober, 2009, Chapter 4, Adv. Immunol., 103: 77-115”, Document D05 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“Weiner and Carter, May 2005, 23(5): 556-557”, Document D36 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“WO 2006/130834 A2 dated Dec. 7, 2006”, Document D02 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“WO 2013/074598 A1 dated May 23, 2013”, Document D06 submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
“WO 2015/100299 A1 dated Jul. 2, 2015” submitted with Notice of Opposition for European Patent No. 3087095 (Application No. 14827372.5), dated May 7, 2020. [cited by applicant]
Balighi et al., “Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?”, Archives of Dermatological Research, Dec. 1, 2018, 311(1): 63-69. [cited by applicant]
Clinicaltrials.gov, “A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients with Pemphigus”, ClinicalTrials.gov Identifier NCT03334058, Nov. 7, 2017, 8 pages. [cited by applicant]
Clinicaltrials.gov, “A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients with Pemphigus”, ClinicalTrials.gov Identifier NCT04598477, Oct. 22, 2020, 10 pages. [cited by applicant]
Combined Search and Examination Report for Great Britain Application No. GB1617270.2, mailed Aug. 3, 2017, 6 pages. [cited by applicant]
Daugherty et al., “Formulation and delivery issues for monoclonal antibody therapeutics”, Adv Drug Deliv Rev., Aug. 7, 2006, 58(5-6): 686-706. [cited by applicant]
Evoli et al., “Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase”, Autoimmunity Reviews, 2013, 12(9): 931-935. [cited by applicant]
International Preliminary Report on Patentability for PCT International Patent Application No. PCT/IB2016/000398, mailed Sep. 12, 2017. [cited by applicant]
International Preliminary Report on Patentability for PCT International Patent Application No. PCT/IB2019/054786, mailed Dec. 8, 2020. [cited by applicant]
International Search Report with Written Opinion for PCT International Patent Application No. PCT/EP2020/065716, mailed Sep. 14, 2020. [cited by applicant]
International Search Report with Written Opinion for PCT International Patent Application No. PCT/IB2016/000398, mailed Aug. 22, 2016. [cited by applicant]
International Search Report with Written Opinion for PCT International Patent Application No. PCT/EP2021/050275, mailed Apr. 8, 2021. [cited by applicant]
Jaretzkl et al., “Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America”, Ann Thorac Surg., Jul. 2000, 70(… [cited by applicant]
Joshi et al., “An Update on Disease Modifying Antirheumatic Drugs”, Inflammation and Allergy—Drug Targets, 2014, 13: 249-261. [cited by applicant]
Kabat et al., “Unusual Distributions of amino Acids in Complementarity-determining (Hypervariable) Segments of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combining Site… [cited by applicant]
Kang et al., “Rapid Formulation Development for Monoclonal Antibodies”, BioProcess International, Apr. 12, 2016, retrieved from url: https://bioprocessintl.com/manufacturing/formulation/rapid-formulation-development-for… [cited by applicant]
Li et al., “Myasthenia gravis: newer therapies offer sustained improvement”, Cleveland Clinic Journal of Medicine, 2013, 80(11): 711-721. [cited by applicant]
Robak et al., “Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis”, Blood, Dec. 7, 2017, 130(Suppl. 1): 15, 59 [cited by applicant]
Rosenwasser et al., “Anti-CD23”, Clinical Reviews in Allergy and Immunology, Aug. 2005, 29(1): 61-72. [cited by applicant]
Shang et al., “Modular protein expression by RNA trans-splicing enables flexible expression of antibody formats in mammalian cells from a dual-host phage display vector”, Protein Engineering, Design & Selection, 2015, v… [cited by applicant]
Silvestri et al., “Treatment-Refractory Myasthenia Gravis”, Journal of Clinical Neuromuscular Disease, Jun. 2014, 15(4): 167-178. [cited by applicant]
Wang et al., “Protein aggregation and its inhibition on biopharmaceutics”, International Journal of Pharmaceutics, Jan. 31, 2005, 289(1-2): 1-30. [cited by applicant]
Tavakolpour, “Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?” Int Immunopharmacol. 2017;53:133-142. [cited by applicant]
Wang et al., “Antibody structure, instability, and formulation,” J Pharm Sci. 2007;96(1):1-26. [cited by applicant]
Verschuuren, “A double-blind placebocontrolled study to evaluate safety and efficacy of fcrn antagonist ARGX-113 in generalized MG,” Elsevier Science Publishers, Amsterdam, NL, 2018. [cited by applicant]
Basta and Dalakas, “High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments,” J Clin Invest. 1994;94(5):1729… [cited by applicant]
Dalakas et al., “High-dose intravenous immune globulin for stiff-person syndrome,” N Engl J Med. 2001;345(26):1870-6. [cited by applicant]
Dalakas, “Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy,” Neurotherapeutics. 2021;18(4):2397-24… [cited by applicant]
Heo, “Efgartigimod: First Approval,” Drugs. 2022;82(3):341-348. [cited by applicant]
Bas Van Der Woning, “R&D Day: Fifth Efgartigimod Indication: Myositis,” ARGENX, Jul. 20, 2021, pp. 23-37. [cited by applicant]
Julien et al., “Abstract No. L10 Efgartigimod Prevents Necrosis and Allows for Muscle Fiber Regeneration in a Humanized Mouse Model of Immune-mediated Necrotizing Myopathy (IMNM),” ACR Meeting Abstracts, ACR Conference … [cited by applicant]
PCT Search Report and Written Opinion for PCT/EP2023/054065, mailed May 3, 2023. [cited by applicant]
Kiessling, “Safety, Pharmacokinetics and Pharmacodynamics of the FCRN Inhibitor UCB7665: a Phase I Study,” Journal of the Peripheral Nervous System. 2017;22(3):226-414. [cited by applicant]
Miyagawa, “Idiopathic Thrombocytopenia Purpura,” Mebio. 2017;34(6):102-107. [cited by applicant]
Alipour-Faz et al., “A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients,” Acta Neurol Belg. 2017;117(1):245-249. [cited by applicant]
Howard et al., “A double-blind placebo-controlled study to evaluate safety and efficacy of FcRn antagonist ARGX-113 (efgartigimod) in generalized myasthenia gravis,” Elsevier 70th Annual Meeting of the American Academmy… [cited by applicant]
Van Faassen, et al., “Serum albumin-binding VH Hs with variable pH sensitivities enable tailored half-life extension of biologics,” Faseb J. 2020 34(6): 8155-8171 doi: 10.1096/fj.201903231R. Epub Apr. 28, 2020. [cited by applicant]
Partial International Search Report issued for International Application No. PCT/EP2023/066180, mailed Sep. 27, 2023. [cited by applicant]
International Search Report and Written Opinion issued for PCT/EP2023/066163, mailed Sep. 27, 2023. [cited by applicant]
Allen et al., “Efgartigimod in chronic inflammatory demyelinating polyneuropathy: Adhere phase 2 trial design”, Muscle and Nerve 20201001 John Wiley and Sons Inc. NLD, Oct. 1, 2020, 62(Suppl 1), abstract (1 page). [cited by applicant]
Anonymous, “A Randomized, Double-Blinded, Placebo-Controlled Trial of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus)”, Jul. 16, 2021, Retrieved from the Internet: URL:https://rctportal.nip… [cited by applicant]
Anonymous, “Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)”, Mar. 27, 2021, ClinicalTrials.gov, Retrieved f… [cited by applicant]
Anonymous, “History of Changes for Study: NCT05267600, A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (Ballad)”, Apr. 14, 2022, p. 1-7. [cited by applicant]
Cited By (3)
US 12,344,678 US 12,403,175 US 12,565,538